• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Statement from Dr. Jonathan Milner on the suspension of the "Vote AGAINST" campaign

    11/1/23 7:00:00 AM ET
    $ABCM
    $DHR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Machinery/Components
    Industrials
    Get the next $ABCM alert in real time by email

    Statement from Dr. Jonathan Milner on the suspension of the "Vote AGAINST" campaign

    CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.16% of the Company, today issued the following statement in relation to the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher").

    "After extensive feedback from the majority of Abcam's shareholders, I have today decided to suspend my "Vote AGAINST" campaign. It has become clear that a significant majority intend to support Danaher's acquisition of Abcam and I respect this decision and will not stand in the way of the deal.

    Although this outcome is not what I envisioned, I accept the result and wish Abcam and Danaher all the best for their future. My sincere gratitude goes to everyone who supported my campaign over the last few months, especially to my shadow Board nominees: your bravery and loyalty have been deeply appreciated. A special thanks also goes to my team of advisors who, acting with integrity and honesty, ensured every shareholder's voice was heard.

    Since the start of my campaign, Abcam's share price increased significantly and, despite the final outcome, I sincerely believe that our campaign has shown that it is possible to stand up to, and call out, an ineffective Board and Management who displayed disregard for the interests of shareholders. It also drew attention to key metrics, governance issues, and the performance of Executive Directors. It is disappointing that, confronted with these facts, Abcam's Board and leadership team decided to simply put the Company up for sale and accept a subpar offer, at the expense of loyal and long-term shareholders. I hope that my actions will inspire shareholders in other companies to hold their Boards to account.

    I extend my heartfelt best wishes to the dedicated staff and loyal customers of Abcam. May they find continued success under the new ownership of Danaher."

    Ends

    Jonathan Milner

    https://abcamfocus.com/

    Investor contact

    Alliance Advisors (Europe)

    T: +44 7733 265 198 / E: [email protected]

    Michael Roper

    Alliance Advisors (US)

    T: +1 917 414 4766

    Thomas Ball

    Peel Hunt LLP

    T: +44 (0) 20 7418 8900

    Christopher Golden / James Steel

    Sohail Akbar / Jock Maxwell Macdonald

    International PR advisers

    ICR Consilium (Europe)

    T: +44 (0)20 3709 5700 / E: [email protected]

    Mary-Jane Elliott / Matthew Neal / Davide Salvi

    ICR (US)

    T: +1 646 677 1811 / E: [email protected]

    Dan McDermott



    Get the next $ABCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABCM
    $DHR

    CompanyDatePrice TargetRatingAnalyst
    Danaher Corporation
    $DHR
    4/10/2025$205.00Equal Weight → Overweight
    Barclays
    Danaher Corporation
    $DHR
    3/21/2025$260.00Neutral → Buy
    Goldman
    Danaher Corporation
    $DHR
    3/14/2025$260.00Hold → Buy
    Stifel
    Danaher Corporation
    $DHR
    2/3/2025Outperform → Mkt Perform
    Raymond James
    Danaher Corporation
    $DHR
    12/23/2024Sector Perform
    Scotiabank
    Danaher Corporation
    $DHR
    12/19/2024$275.00Buy
    Guggenheim
    Danaher Corporation
    $DHR
    12/13/2024$290.00Neutral → Buy
    BofA Securities
    Danaher Corporation
    $DHR
    10/31/2024$285.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings